Molecular Partners AG Logo

Molecular Partners AG

Pioneering DARPin protein drugs for complex diseases in oncology and virology.

MOLN | SW

Overview

Corporate Details

ISIN(s):
CH0256379097 (+1 more)
LEI:
875500AXMLDAZ4D21744
Country:
Switzerland
Address:
Wagistrasse 14, 8952 Schlieren
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Molecular Partners AG is a clinical-stage biopharmaceutical company that pioneers the design and development of DARPin therapeutics, a novel class of custom-built protein drugs. The company leverages its proprietary platform to create potent and specific therapies engineered to address complex medical challenges, particularly in oncology and virology, that other drug modalities cannot readily treat. Molecular Partners develops its pipeline of innovative therapeutic candidates independently and in collaboration with global partners to deliver new treatments for patients with serious diseases.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2020-07-07 07:25
Share Issue/Capital Change
Molecular Partners AG: Molecular Partners Successfully Completes the Launch of …
English 17.3 KB
2020-04-19 23:15
Regulatory News Service
Molecular Partners Initiates Anti-COVID-19 Therapeutic Program Leveraging Multi…
English 12.0 KB

Automate Your Workflow. Get a real-time feed of all Molecular Partners AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Molecular Partners AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-09-09 N/A Executive member Sell None 47,784.80 CHF
2024-09-09 N/A Executive member Sell None 13,822.40 CHF
2024-04-02 N/A Executive member Sell None 243,000.00 CHF
2023-11-01 N/A Executive member Buy None 31,760.55 CHF
2022-02-15 N/A Executive member Sell None 2,410,500.00 CHF
2022-02-15 N/A Executive member Sell None 1,607,000.00 CHF

Peer Companies

Company Country Ticker View
Read Gene Spolka Akcyjna Logo
Develops DNA tests to identify genetic cancer risk for early detection and prevention.
Poland RDG
RELIEF Therapeutics Holding AG Logo
Developing and commercializing novel therapies for rare and ultra-rare diseases.
Switzerland RLF
RYVU Therapeutics S.A. Logo
Clinical-stage drug discovery company developing novel small molecule therapies for oncology.
Poland RVU
SAREUM HOLDINGS PLC Logo
Clinical-stage developer of kinase inhibitors for autoimmune disease & cancer.
United Kingdom SAR
SCANCELL HOLDINGS PLC Logo
Developing therapeutic vaccines and antibodies for cancer and infectious diseases.
United Kingdom SCLP
SCIENCE GROUP PLC Logo
International science & tech consultancy providing advisory, R&D, and product development.
United Kingdom SAG
Selvita S.A. Logo
Preclinical CRO offering integrated drug discovery and development services for life sciences.
Poland SLV
Simris Group AB Logo
Develops novel cyanobacteria-based payloads for Antibody-Drug Conjugates to treat cancer.
Sweden SIMRIS
SKINBIOTHERAPEUTICS PLC Logo
A life science company developing microbiome-based skin health products and supplements.
United Kingdom SBTX
Terranet B Logo
Develops ultra-fast ADAS anti-collision technology for automakers to protect vulnerable road users.
Sweden TERRNT

Talk to a Data Expert

Have a question? We'll get back to you promptly.